About:denisebell

Posts by denisebell :

RenalytixAI’s KidneyIntelX™ Demonstrates Effectiveness In Monitoring Therapeutic Response in kidney health for Adults with type 2 diabetes

Posted on by Denise Bell

Renalytix has announced new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and improvements in kidney health in adults with type 2 diabetes. The data from an international study of 1,100 individuals with diabetic kidney disease (DKD) in the CANagliflozin Cardiovascular Assessment Study (CANVAS), was presented at the American Diabetes Association 81st Scientific Sessions […]

Read More

Phoenix PharmaLabs Raises More than $1 Million for Continued Development of Non-Addictive Opioids

Posted on by Denise Bell

Phoenix PharmaLabs, Inc. has completed a second successful round of financing raising $1.07 million via the Netcapital equity funding portal to continue development of two non-addictive opioids to treat acute and chronic pain. “More than a thousand investors, many of whom invested in our previous funding, participated in this offering, indicating to us they did […]

Read More

Turner Innovations Awarded STTR Phase 1 Contract from US Air Force

Posted on by Denise Bell

Turner Imaging Systems has won a small Business Technology Transfer (STTR) Phase I contract from the U.S. Air Force. Turner will use the non-dilutive funds to develop a next generation compact, highly portable, battery-powered full-body fluoroscopic X-ray (Smart-C) to help Special Operations Surgical Teams, Army Forward Surgical Teams (FSTs), and Navy Fleet Surgical Teams, save […]

Read More

nView s1 Reaches its 50th Surgery, Gets Navigation Capability

Posted on by Denise Bell

The nView s1, nView medical’s breakthrough imaging system, reached its 50th surgery. Twelve surgeons across three leading pediatric hospitals have used nView’s insta-3D™ technology on procedures ranging from spinal deformity corrections, to discectomies, periacetabular osteotomies and extremity procedures. nView medical CEO, Cristian Atria, said, “To celebrate the 50th surgery milestone we gave the nView s1 […]

Read More

Launch of Xenter Therapeutics

Posted on by Denise Bell

Following the close of $12M in Series A funding, Xenter, Inc., the world’s first start-up Device-Data-Drug healthcare technologies company, announced the launch of the Xenter Therapeutics business unit. Xenter Therapeutics will lead the therapeutic drug element of Xenter’s mission and vision and is headed by President and Xenter board member David J. Bearss, PhD, a biotech […]

Read More

Blackrock Neurotech Closes $10M Financing Round To Advance Development Of Its World-Leading Brain-Computer Interface (BCI) Technology

Posted on by Denise Bell

Blackrock Neurotech, the world’s leading platform for brain-computer interface (BCI) technology and manufacturing, has closed a $10 million financing round, led by Christian Angermayer’s re.Mind Capital with participation from Peter Thiel, German entrepreneur Tim Sievers, and Sorenson Impact’s University Venture Fund II. The funding will further expand programs on the Blackrock platform, including clinical studies […]

Read More

Biden Administration Recommends Policy Changes to Secure U.S. Pharmaceutical Supply Chain

Posted on by Denise Bell

In last week’s BioUtah News and Events, we highlighted the Biden Administration’s formation of a task force to address a range of supply chain issues. This week, we share the findings of the administration’s 100-day assessment of critical supply chains, undertaken pursuant to President Biden’s February 2021 “America’s Supply Chains” executive order addressing supply chain […]

Read More

ARUP Celebrates Opening of a New State-of-the-Art Laboratory Facility in Salt Lake City

Posted on by Denise Bell

Founded in 1984, ARUP Laboratories, one of the nation’s largest reference laboratories, on Tuesday held a ribbon cutting ceremony to officially open its new four-story, 220,000-square-foot laboratory facility located in University of Utah Research Park. The newly constructed facility is the crown jewel of eight properties ARUP now owns and operates as Research Park’s largest […]

Read More

Elute Receives FDA Authorization For Its First Clinical Trial Using Antibiotic Eluting Bone Void Filler

Posted on by Denise Bell

Elute has received an Investigational Device Exemption (IDE) authorization from the FDA to use its EP Granules with TobramycinTM in a pivotal clinical trial. This IDE investigates the use of a resorbable bone void filler that delivers a broad-spectrum antibiotic in the surgical treatment of bone infections following hip or knee replacements. This is the […]

Read More